Ensign Group Q2 Revenue Hits $1.44B, Raises FY2026 Guidance to $5.87B-$5.92B
ENSG sits 24% above its 52-week low of $136.93.
Summary
Ensign Group posted strong Q2 2026 results with revenue of $1.44 billion and raised its full-year revenue guidance, but the filing also reveals a DOJ investigation and a derivative lawsuit that add risk to the story. Adjusted EPS was $1.92, up 20.8% year over year, and the company raised EPS guidance to $7.75-$7.85 from $7.48-$7.62.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Adjusted EPS was $1.92, up 20.8% year over year; adjusted net income was $114.3 million, up 22.5%. The company raised EPS guidance to $7.75-$7.85 from $7.48-$7.62.
Key Events · Earnings and Guidance · ENSG
-
New · · SEC 8-K
Adjusted EPS and Net Income Reported
Adjusted EPS was $1.92, up 20.8% year over year, and adjusted net income was $114.3 million, up 22.5%.
-
Updated · · SEC 8-K
FY2026 Revenue and EPS Guidance Raised
Management raised full-year revenue guidance to $5.87-$5.92 billion and raised EPS guidance to $7.75-$7.85 from $7.48-$7.62.
-
Q2 Revenue and Earnings Beat
Driven by occupancy gains and higher patient acuity, revenue grew 17.3% to $1.44 billion, with net income of $99.7 million and diluted EPS of $1.68.
-
$100M Buyback Program Launched
The board authorized a $100 million stock repurchase program, with $40 million executed in Q2 at an average price of $155.54 per share.
-
DOJ Investigation Disclosed
A Civil Investigative Demand from the DOJ is examining Medicare and Texas Medicaid billing practices from 2016 to present.
Analysis · ENSG · Industrial Applications And Services
A strong second quarter saw revenue climb 17.3% to $1.44 billion and diluted EPS reach $1.68, outpacing the prior year's $1.44. Adjusted EPS was $1.92, up 20.8% year over year, with adjusted net income of $114.3 million, up 22.5%. Full-year revenue guidance was raised to $5.87-$5.92 billion, adding top-line clarity alongside the raised EPS guidance of $7.75-$7.85, up from $7.48-$7.62. Confidence in the outlook was underscored by a new $100 million buyback program, with $40 million already deployed, even as regulatory headwinds mount from the One Big Beautiful Bill and multiple government investigations. The filing details a DOJ Civil Investigative Demand into Medicare and Texas Medicaid billing, a derivative shareholder lawsuit, and extensive new CMS rulemaking that could pressure margins. While operational momentum is clear, the legal and regulatory overhang introduces significant uncertainty.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.5% of the 1055 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENSG was trading at $169.99 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $10.1B. The 52-week trading range was $136.93 to $218.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.